CARM
Price
$1.37
Change
-$0.03 (-2.14%)
Updated
May 16, 6:59 PM EST
CRSP
Price
$55.67
Change
-$1.29 (-2.26%)
Updated
May 16, 6:59 PM EST
74 days until earnings call
Ad is loading...

CARM vs CRSP

Header iconCARM vs CRSP Comparison
Open Charts CARM vs CRSPBanner chart's image
Carisma Therapeutics
Price$1.37
Change-$0.03 (-2.14%)
Volume$96.02K
CapitalizationN/A
CRISPR Therapeutics AG
Price$55.67
Change-$1.29 (-2.26%)
Volume$541.08K
CapitalizationN/A
View a ticker or compare two or three
CARM vs CRSP Comparison Chart

Loading...

CARMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CRSPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CARM vs. CRSP commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and CRSP is a Hold.

COMPARISON
Comparison
May 17, 2024
Stock price -- (CARM: $1.40 vs. CRSP: $56.96)
Brand notoriety: CARM and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 127% vs. CRSP: 108%
Market capitalization -- CARM: $58.16M vs. CRSP: $4.84B
CARM [@Biotechnology] is valued at $58.16M. CRSP’s [@Biotechnology] market capitalization is $4.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $592.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, both CARM and CRSP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 3 TA indicator(s) are bullish while CRSP’s TA Score has 6 bullish TA indicator(s).

  • CARM’s TA Score: 3 bullish, 3 bearish.
  • CRSP’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than CARM.

Price Growth

CARM (@Biotechnology) experienced а -9.68% price change this week, while CRSP (@Biotechnology) price change was +6.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +4.69%, and the average quarterly price growth was +62.76%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

CRSP is expected to report earnings on Jul 29, 2024.

Industries' Descriptions

@Biotechnology (+3.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CARM with price predictions.
OPEN
A.I.dvisor published
a Summary for CRSP with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CRSP($4.84B) has a higher market cap than CARM($58.2M). CRSP YTD gains are higher at: -9.010 vs. CARM (-52.218).
CARMCRSPCARM / CRSP
Capitalization58.2M4.84B1%
EBITDAN/AN/A-
Gain YTD-52.218-9.010580%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CARM vs CRSP: Fundamental Ratings
CARM
CRSP
OUTLOOK RATING
1..100
5423
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
9381
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CARM's Valuation (52) in the null industry is in the same range as CRSP (62) in the Biotechnology industry. This means that CARM’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that CRSP’s stock grew similarly to CARM’s over the last 12 months.

CRSP's SMR Rating (92) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that CRSP’s stock grew similarly to CARM’s over the last 12 months.

CRSP's Price Growth Rating (81) in the Biotechnology industry is in the same range as CARM (93) in the null industry. This means that CRSP’s stock grew similarly to CARM’s over the last 12 months.

CRSP's P/E Growth Rating (80) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that CRSP’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMCRSP
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
CARMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CRSPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PAGDX89.361.19
+1.35%
Permanent Portfolio Aggressive Growth A
BMSTX14.740.18
+1.24%
MFS Blended Research Mid Cap Eq R3
GQETX32.340.38
+1.19%
GMO Quality III
PGEOX24.810.25
+1.02%
George Putnam Balanced A
PMIRX10.440.08
+0.77%
Putnam Multi-Asset Income R

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with NTLA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-4.11%
NTLA - CARM
43%
Loosely correlated
+1.90%
PRME - CARM
42%
Loosely correlated
+1.50%
MLYS - CARM
38%
Loosely correlated
+0.08%
FOLD - CARM
38%
Loosely correlated
+3.54%
FULC - CARM
36%
Loosely correlated
+4.30%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been loosely correlated with BEAM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+2.24%
BEAM - CRSP
51%
Loosely correlated
+1.26%
AXON - CRSP
49%
Loosely correlated
-0.85%
AGEN - CRSP
49%
Loosely correlated
+0.75%
INO - CRSP
46%
Loosely correlated
+14.45%
NTLA - CRSP
44%
Loosely correlated
+1.90%
More